SRC and cancer: In agreement, our results from cell cycle assay in A549 cells showed that Dasatinib (10 nM) significantly increased the proportion of cells at G1 phase in comparison with the control group (Fig 1C), suggesting the direct arrest of cell cycle progression by Src inhibition in cancer cells.